Huntington’s Disease

Huntington’s Disease

UniQure's AMT-130 Achieves Landmark Success in Huntington's Disease Trial, QURE Stock Surges 194%

UniQure’s AMT-130 gene therapy slowed Huntington’s disease progression by 75% in a Phase I/II trial, with favorable cognitive and motor outcomes, manageable safety, and FDA Breakthrough Therapy and RMAT designations. BLA submission planned in early 2026.